223 related articles for article (PubMed ID: 20796312)
41. Microbiological and epidemiological characterization of imipenem-resistant Pseudomonas aeruginosa strains from a Brazilian tertiary hospital: report from the SENTRY Antimicrobial Surveillance Program.
Ribeiro J; Mendes RE; Domingos R; França E; Silbert S; Jones RN; Sader HS
J Chemother; 2006 Oct; 18(5):461-7. PubMed ID: 17127220
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
Chastre J; Wunderink R; Prokocimer P; Lee M; Kaniga K; Friedland I
Crit Care Med; 2008 Apr; 36(4):1089-96. PubMed ID: 18379232
[TBL] [Abstract][Full Text] [Related]
43. In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem.
Bretonnière C; Boutoille D; Caillon J; Desessard C; Guitton C; Potel G; Jacqueline C
Int J Antimicrob Agents; 2014 Sep; 44(3):218-21. PubMed ID: 25108877
[TBL] [Abstract][Full Text] [Related]
44. Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to β-lactams in ICU patients: A pilot study.
Dupont H; Marciniak S; Zogheib E; Mammeri H; Friggeri A; Ammenouche N; Levrard M; Airapetian N; Tinturier F; Mahjoub Y
Anaesth Crit Care Pain Med; 2015 Jun; 34(3):141-4. PubMed ID: 26004874
[TBL] [Abstract][Full Text] [Related]
45. Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections.
Maurice NM; Bedi B; Sadikot RT
Am J Respir Cell Mol Biol; 2018 Apr; 58(4):428-439. PubMed ID: 29372812
[TBL] [Abstract][Full Text] [Related]
46. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study.
Lima AL; Oliveira PR; Paula AP; Dal-Paz K; Rossi F; Zumiotti AV
Infect Control Hosp Epidemiol; 2009 May; 30(5):487-90. PubMed ID: 19335227
[TBL] [Abstract][Full Text] [Related]
47. Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia.
Martin-Loeches I; Bisanti A; Diaz E; Rodriguez A
Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1177-1185. PubMed ID: 32662691
[TBL] [Abstract][Full Text] [Related]
48. Pseudomonas aeruginosa Pneumonia: Evolution of Antimicrobial Resistance and Implications for Therapy.
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2022 Apr; 43(2):191-218. PubMed ID: 35062038
[No Abstract] [Full Text] [Related]
49. Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
Micaëlo M; Brossier F; Bréchot N; Luyt CE; Lu Q; Monsel A; Jarlier V; Aubry A
Med Mal Infect; 2018 Aug; 48(5):365-371. PubMed ID: 29628176
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients.
Zavascki AP; Cruz RP; Goldani LZ
J Hosp Infect; 2005 Feb; 59(2):96-101. PubMed ID: 15620442
[TBL] [Abstract][Full Text] [Related]
51. Prevalence of Pseudomonas aeruginosa and antimicrobial-resistant Pseudomonas aeruginosa in patients with pneumonia in mainland China: a systematic review and meta-analysis.
Ding C; Yang Z; Wang J; Liu X; Cao Y; Pan Y; Han L; Zhan S
Int J Infect Dis; 2016 Aug; 49():119-28. PubMed ID: 27329135
[TBL] [Abstract][Full Text] [Related]
52. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
[TBL] [Abstract][Full Text] [Related]
53. Pseudomonas aeruginosa nosocomial pneumonia: impact of pneumonia classification.
Micek ST; Kollef MH; Torres A; Chen C; Rello J; Chastre J; Antonelli M; Welte T; Clair B; Ostermann H; Calbo E; Wunderink R; Menichetti F; Schramm G; Menon V
Infect Control Hosp Epidemiol; 2015 Oct; 36(10):1190-7. PubMed ID: 26190444
[TBL] [Abstract][Full Text] [Related]
54. Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections.
Onguru P; Erbay A; Bodur H; Baran G; Akinci E; Balaban N; Cevik MA
J Korean Med Sci; 2008 Dec; 23(6):982-7. PubMed ID: 19119440
[TBL] [Abstract][Full Text] [Related]
55. Multidrug-resistant Pseudomonas aeruginosa and mortality in mechanically ventilated ICU patients.
Denis JB; Lehingue S; Pauly V; Cassir N; Gainnier M; Léone M; Daviet F; Coiffard B; Baron S; Guervilly C; Forel JM; Roch A; Papazian L
Am J Infect Control; 2019 Sep; 47(9):1059-1064. PubMed ID: 30962023
[TBL] [Abstract][Full Text] [Related]
56. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
[TBL] [Abstract][Full Text] [Related]
57. Impact of intensive care unit relocation and role of tap water on an outbreak of Pseudomonas aeruginosa expressing OprD-mediated resistance to imipenem.
Tran-Dinh A; Neulier C; Amara M; Nebot N; Troché G; Breton N; Zuber B; Cavelot S; Pangon B; Bedos JP; Merrer J; Grimaldi D
J Hosp Infect; 2018 Nov; 100(3):e105-e114. PubMed ID: 29857026
[TBL] [Abstract][Full Text] [Related]
58. Likelihood of inadequate treatment: a novel approach to evaluating drug-resistance patterns.
Burgmann H; Stoiser B; Heinz G; Schenk P; Apfalter P; Zedtwitz-Liebenstein K; Frass M; Carmeli Y
Infect Control Hosp Epidemiol; 2009 Jul; 30(7):672-7. PubMed ID: 19496644
[TBL] [Abstract][Full Text] [Related]
59. Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.
Fraile-Ribot PA; Zamorano L; Orellana R; Del Barrio-Tofiño E; Sánchez-Diener I; Cortes-Lara S; López-Causapé C; Cabot G; Bou G; Martínez-Martínez L; Oliver A;
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31740559
[TBL] [Abstract][Full Text] [Related]
60. Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia.
Combes A; Luyt CE; Fagon JY; Wolff M; Trouillet JL; Chastre J
Intensive Care Med; 2006 Dec; 32(12):1970-8. PubMed ID: 16957901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
